应《网络安全法》要求，自2017年10月1日起，未进行实名认证将不得使用互联网跟帖服务。为保障您的帐号能够正常使用，请尽快对帐号进行手机号验证，感谢您的理解与支持！

24小时热门版块排行榜    

小木虫论坛-学术科研互动平台 » 生物医药区 » 新药研发 » 临床研究 » 求linifanib最新临床情况
51/1返回列表
查看: 445  |  回复: 2
只看楼主 @他人 存档 新回复提醒 (忽略) 收藏    在APP中查看
当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖

也到

木虫 (小有名气)

无欲无求

[求助] 求linifanib最新临床情况 已有1人参与

求linifanib最新临床情况，最好包括临床类型及几期
还有这种药物的发展前景
回复此楼

» 猜你喜欢

» 本主题相关价值贴推荐，对您同样有帮助:
不知所措
1楼 2014-08-19 19:34:32
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

ovk999

金虫 (小有名气)

【答案】应助回帖

感谢参与，应助指数 +1
AbbVie is developing linifanib, an orally active multi-targeted receptor tyrosine kinase inhibitor, for the treatment of cancer, including non-small cell lung cancer, breast cancer, colorectal cancer, renal cancer and hepatocellular carcinoma. Linifanib was being developed in collaboration with Genentech; however, development later reverted to Abbott. Linifanib acts as both a vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinase inhibitor. It has been shown to stop disease progression by limiting tumour blood-flow. Linifanib is hydrophobic, but is oxidised in the body to A 849529, a hydrophilic metabolite that includes both carboxyl and amino groups. Linifanib is in phase II development for breast, renal, colorectal and non-small cell lung cancer. The compound was being investigated in a phase III trial for hepatocellular carcinoma, but the trial has been terminated.
赞一下 回复此楼

» 本帖附件资源列表

  • 欢迎监督和反馈：小木虫仅提供交流平台，不对该内容负责。
    本内容由用户自主发布，如果其内容涉及到知识产权问题，其责任在于用户本人，如对版权有异议，请联系邮箱：xiaomuchong@tal.com
  • 附件 1 : Linifanib-临床开发情况.docx
    • 2014-08-20 14:47:24, 87.78 K
3楼2014-08-20 14:46:14
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
查看全部 3 个回答

fbifbeaifb

新虫 (初入文坛)
这个只能是汤森数据库才能查到了
赞一下 回复此楼
2楼2014-08-20 10:46:28
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
查看全部 3 个回答
普通表情 龙 兔 虎 猫
最具人气热帖推荐 [查看全部] 作者 回/看 最后发表
[教师之家] 售SCI一区T0P文章，我:8.O.55.1.O.54,科目齐全,可+急 +3 5sJFDKp2kwuI 2026-11-06 5/250 2026-11-07 17:01 by Xc2FxHsHkBNc
[考博] 售SCI文章，我:8O.5.5.1O.54,科目全,可十急 +3 5sJFDKp2kwuI 2026-11-06 5/250 2026-11-07 16:06 by Xc2FxHsHkBNc
[教师之家] 延安大学回应“副教授留绝笔信”：确已离世，正核实举报内容 +3 yexuqing 2026-11-04 5/250 2026-11-07 13:22 by 苏东坡二世
[公派出国] 售SCI文章，我:8O5.5.1.O.54,科目齐全,可+急 +8 ncTVBM6AOJHF 2026-11-04 23/1150 2026-11-07 06:49 by Equinoxhua
[公派出国] 售一区SCI文章T0P，我:8O.551.O54,科目全,可十急 +4 ELBZ6WwEaRj6 2026-11-05 5/250 2026-11-06 16:43 by 5sJFDKp2kwuI
[考博] 售SCI一区文章，我:8O5.5.1.O5.4,科目全,可伽急 +6 ELBZ6WwEaRj6 2026-11-05 8/400 2026-11-06 16:34 by 5sJFDKp2kwuI
[公派出国] 售SCI一区T0P文章，我:8.O.55.1.O.54,科目齐全,可+急 +5 ttH3f1oA6ace 2026-11-04 10/500 2026-11-06 16:12 by 5sJFDKp2kwuI
[公派出国] 售SCI一区文章，我:8.O.551.O.5.4,科目全,可伽急 +6 ttH3f1oA6ace 2026-11-04 12/600 2026-11-06 16:10 by 5sJFDKp2kwuI
[考博] 售SCI一区T0P文章，我:8.O55.1.O.54,科目全,可十急 +7 ncTVBM6AOJHF 2026-11-04 17/850 2026-11-06 13:47 by BkA9Bi5cMhkD
[硕博家园] 售SCI一区文章，我:8.O.551.O.5.4,科目全,可伽急 +6 ncTVBM6AOJHF 2026-11-04 11/550 2026-11-06 13:47 by BkA9Bi5cMhkD
[考研] 售一区SCI文章T0P，我:8O.551.O54,科目全,可十急 +8 ncTVBM6AOJHF 2026-11-04 18/900 2026-11-06 13:36 by BkA9Bi5cMhkD
[考研] 售SCI一区T0P文章，我:8.O.55.1.O.54,科目齐全,可+急 +5 ELBZ6WwEaRj6 2026-11-05 10/500 2026-11-06 12:32 by BkA9Bi5cMhkD
[硕博家园] 售一区SCI文章T0P，我:8O.551.O54,科目全,可十急 +3 ELBZ6WwEaRj6 2026-11-05 5/250 2026-11-06 09:01 by 2lRNluKrJpwL
[考研] 售SCI-T0P文章，我:8O.5.5.1.O.54,科目齐全,可+急 +4 ttH3f1oA6ace 2026-11-04 14/700 2026-11-06 05:11 by qL1cU46YIdK0
[考博] 售SCI一区T0P文章，我:8.O.55.1.O54,科目全,可伽急 +4 kvewwGtKktqB 2026-11-04 11/550 2026-11-06 05:10 by qL1cU46YIdK0
[硕博家园] 售SCI一区文章，我:8O5.5.1.O5.4,科目全,可伽急 +4 ncTVBM6AOJHF 2026-11-04 12/600 2026-11-06 04:47 by qL1cU46YIdK0
[公派出国] 售SCI-T0P文章，我:8O.5.5.1.O.54,科目齐全,可+急 +3 ELBZ6WwEaRj6 2026-11-04 9/450 2026-11-06 02:15 by qL1cU46YIdK0
[考研] 售SCI一区T0P文章，我:8.O55.1.O.54,科目全,可十急 +4 ttH3f1oA6ace 2026-11-04 10/500 2026-11-06 02:04 by qL1cU46YIdK0
[硕博家园] 售SCI-T0P文章，我:8O.5.5.1.O.54,科目齐全,可+急 +3 ttH3f1oA6ace 2026-11-04 9/450 2026-11-06 02:02 by qL1cU46YIdK0
[考研] 售一区SCI文章T0P，我:8O.551.O54,科目全,可十急 +5 ncTVBM6AOJHF 2026-11-04 12/600 2026-11-06 01:42 by qL1cU46YIdK0
信息提示
关闭
请填处理意见
关闭